DDInter1758 DDInter1676
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Telithromycin {u} (Compound) resembles {v} (Compound) Azithromycin
Telithromycin {u} (Compound) binds {v} (Gene) CYP1A2
Telithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Ketolides
Telithromycin {u} (Compound) causes {v} (Side Effect) Bundle branch block
Telithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paricalcitol
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Telithromycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Telithromycin (Compound) resembles Azithromycin (Compound)
Telithromycin (Compound) binds CYP1A2 (Gene)
Telithromycin (Compound) is included by Ketolides (Pharmacologic Class)
Telithromycin (Compound) causes Bundle branch block (Side Effect)
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Telithromycin may lead to a major life threatening interaction when taken with Betrixaban
Telithromycin may lead to a major life threatening interaction when taken with Terfenadine
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin